Crescent Biopharma (CBIO)
NASDAQ:CBIO
Want to see CBIO full AI Analyst Report?
Top Page
Crescent Biopharma
(NASDAQ:CBIO)
Select Model
Select Model
Rating:56Neutral
Price Target:
$21.50
▲(1.03% Upside)
Action:ReiteratedDate:04/30/26
The score is driven by a strong technical uptrend and a much improved revenue base with high gross margins and low leverage. These positives are tempered by still-severe losses and negative free cash flow, and valuation signals remain weak due to negative earnings and no dividend yield data.
Positive Factors
Revenue growth with very high gross margins
Sustained revenue increase alongside ~96% gross margins indicates strong unit economics and successful early commercialization. High gross margins provide durable operating leverage potential, enabling the company to scale revenue without proportional COGS increases as trials convert to commercial sales.
Negative Factors
Deep and persistent negative profitability
Very large negative margins reflect that operating costs vastly exceed current revenue, a structural weakness that can erode shareholder equity over time. Prolonged unprofitability necessitates external funding, increases dilution risk, and delays the point at which the business can self-fund growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth with very high gross margins
Sustained revenue increase alongside ~96% gross margins indicates strong unit economics and successful early commercialization. High gross margins provide durable operating leverage potential, enabling the company to scale revenue without proportional COGS increases as trials convert to commercial sales.
Read all positive factors
Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$577.04M
Dividend YieldN/A
Average Volume (3M)145.41K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue GrowthN/A
EPS Growth73.87%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.08
Price to Sales (P/S)113.89
P/FCF Ratio-17.05
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue9.40
Enterprise Value/Gross Profit9.80
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$29.40Price Target Upside38.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Crescent Biopharma Business Overview & Revenue Model
Company Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company ha...
Crescent Biopharma Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
67
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.41M | 10.84M | 0.00 | 10.00K | 75.00K | 1.16M |
| Gross Profit | 39.72M | 10.76M | -35.17K | 10.00K | 75.00K | 1.16M |
| EBITDA | -169.91M | -149.67M | 0.00 | -39.12M | -47.20M | -63.18M |
| Net Income | -138.79M | -149.94M | -71.47M | -36.90M | -46.69M | -63.43M |
Balance Sheet | ||||||
| Total Assets | 199.13M | 240.29M | 35.62M | 45.32M | 51.81M | 94.35M |
| Cash, Cash Equivalents and Short-Term Investments | 189.16M | 213.19M | 34.77M | 41.79M | 47.87M | 90.25M |
| Total Debt | 1.54M | 1.64M | 37.48M | 808.40K | 918.55K | 1.92M |
| Total Liabilities | 15.28M | 37.28M | 51.10M | 6.90M | 8.88M | 12.74M |
| Stockholders Equity | 183.85M | 203.01M | 5.31M | 38.41M | 42.93M | 81.60M |
Cash Flow | ||||||
| Free Cash Flow | -27.36M | -72.45M | -31.11M | -34.90M | -46.54M | -57.50M |
| Operating Cash Flow | -26.41M | -71.53M | -31.10M | -34.88M | -46.46M | -57.49M |
| Investing Cash Flow | -81.07M | -72.92M | 20.03K | -21.39K | -84.19K | -14.94K |
| Financing Cash Flow | 316.04M | 322.98M | 5.40K | 28.82M | 4.16M | 10.72M |
Crescent Biopharma Technical Analysis
Positive
21.28
Price Trends
13.36
Positive
12.88
Positive
12.90
Positive
Market Momentum
2.08
Negative
73.91
Negative
74.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Positive. The current price of 21.28 is above the 20-day moving average (MA) of 16.95, above the 50-day MA of 13.36, and above the 200-day MA of 12.90, indicating a bullish trend. The MACD of 2.08 indicates Negative momentum. The RSI at 73.91 is Negative, neither overbought nor oversold. The STOCH value of 74.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBIO.
Crescent Biopharma Risk Analysis
Crescent Biopharma disclosed 68 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crescent Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $245.84M | 4.04 | 55.68% | ― | 161.14% | ― | |
56 Neutral | $577.04M | -8.24 | -122.12% | ― | ― | 73.87% | |
53 Neutral | $95.51M | -1.18 | 9999.00% | ― | -100.00% | -40.01% | |
52 Neutral | $222.38M | -3,008.78 | -169.64% | ― | 1169.22% | 22.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $144.17M | -0.86 | -55.02% | ― | -51.24% | 30.42% |
* Healthcare Sector Average
CBIO
Crescent Biopharma
20.94
-4.21
-16.74%
CGEN
Compugen
2.60
1.00
62.50%
FATE
Fate Therapeutics
1.24
-0.04
-3.13%
OBIO
Orchestra BioMed Holdings
3.80
0.83
27.95%
GUTS
Fractyl Health, Inc.
0.60
-0.67
-52.60%
ACTU
Actuate Therapeutics, Inc.
2.88
-6.32
-68.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.